BTX BioTime Inc.

+0.07  (+6%)
Previous Close 1.13
Open 1.12
Price To Book 1.1
Market Cap 179,571,433
Shares 149,642,861
Volume 397,963
Short Ratio 20.08
Av. Daily Volume 507,495

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due 2019 and 2020.
Non-small cell lung cancer (NSCLC)
Phase 1/2 12-month data from cohorts 3 and 4 released July 31, 2018. Intends to meet with FDA regarding next steps.
Cervical spinal cord injury
Phase 1/2 enrolment to be completed 2019.
Dry age-related macular degeneration (AMD)

Latest News

  1. BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System
  2. BioTime Conducts Sale of Shares in OncoCyte Corporation
  3. Should You Be Excited About BioTime, Inc.'s (NYSEMKT:BTX) 35% Return On Equity?
  4. Is Forbuild SA’s (WSE:BTX) 16% ROCE Any Good?
  5. Edited Transcript of BTX earnings conference call or presentation 9-May-19 8:30pm GMT
  6. BioTime Announces Appointment of General Counsel
  7. Don't Sell Forbuild SA (WSE:BTX) Before You Read This
  8. BioTime (BTX) Q1 2019 Earnings Call Transcript
  9. Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
  10. BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
  11. BioTime (BTX) Tops Q1 Earnings and Revenue Estimates
  12. BioTime: 1Q Earnings Snapshot
  13. BioTime Reports First Quarter 2019 Financial Results and Provides Business Update
  14. BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury
  15. BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
  16. Will BioTime (BTX) Report Negative Q1 Earnings? What You Should Know
  17. BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting
  18. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
  19. BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference
  20. Did Changing Sentiment Drive BioTime's (NYSEMKT:BTX) Share Price Down A Worrying 58%?